Search research articles
Contact Us
Filters
Showing results (41-50 of 48) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 48 results.
Science (New York, N.Y.)
|
October 23, 1998
An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits
J R Wetterau, R E Gregg, T W Harrity, et al.
ACS Medicinal Chemistry Letters
|
June 22, 2016
Discovery and Preclinical Evaluation of BMS-711939, an Oxybenzylglycine Based PPARα Selective Agonist
Yan Shi, Jun Li, Lawrence J Kennedy, et al.
Journal of Medicinal Chemistry
|
March 21, 2019
Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK)
Scott H Watterson, Qingjie Liu, Myra Beaudoin Bertrand, et al.
Journal of Medicinal Chemistry
|
September 2, 2016
Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton's Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers
Scott H Watterson, George V De Lucca, Qing Shi, et al.
Journal of Medicinal Chemistry
|
March 12, 2010
Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453)
Jun Li, Lawrence J Kennedy, Yan Shi, et al.
Journal of Medicinal Chemistry
|
October 23, 2019
Rationally Designed, Conformationally Constrained Inverse Agonists of RORγt-Identification of a Potent, Selective Series with Biologic-Like in Vivo Efficacy
David Marcoux, James J-W Duan, Qing Shi, et al.
Journal of Medicinal Chemistry
|
May 26, 2017
Identification of a Potent, Selective, and Efficacious Phosphatidylinositol 3-Kinase δ (PI3Kδ) Inhibitor for the Treatment of Immunological Disorders
Qingjie Liu, Qing Shi, David Marcoux, et al.
Journal of Medicinal Chemistry
|
February 18, 2022
Discovery of a Partial Glucokinase Activator Clinical Candidate: Diethyl ((3-(3-((5-(Azetidine-1-carbonyl)pyrazin-2-yl)oxy)-5-isopropoxybenzamido)-1<i>H</i>-pyrazol-1-yl)methyl)phosphonate (BMS-820132)
Yan Shi, Ying Wang, Wei Meng, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 48) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 48 results.
Science (New York, N.Y.)
|
October 23, 1998
An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits
J R Wetterau, R E Gregg, T W Harrity, et al.
ACS Medicinal Chemistry Letters
|
June 22, 2016
Discovery and Preclinical Evaluation of BMS-711939, an Oxybenzylglycine Based PPARα Selective Agonist
Yan Shi, Jun Li, Lawrence J Kennedy, et al.
Journal of Medicinal Chemistry
|
March 21, 2019
Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK)
Scott H Watterson, Qingjie Liu, Myra Beaudoin Bertrand, et al.
Journal of Medicinal Chemistry
|
September 2, 2016
Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton's Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers
Scott H Watterson, George V De Lucca, Qing Shi, et al.
Journal of Medicinal Chemistry
|
March 12, 2010
Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453)
Jun Li, Lawrence J Kennedy, Yan Shi, et al.
Journal of Medicinal Chemistry
|
October 23, 2019
Rationally Designed, Conformationally Constrained Inverse Agonists of RORγt-Identification of a Potent, Selective Series with Biologic-Like in Vivo Efficacy
David Marcoux, James J-W Duan, Qing Shi, et al.
Journal of Medicinal Chemistry
|
May 26, 2017
Identification of a Potent, Selective, and Efficacious Phosphatidylinositol 3-Kinase δ (PI3Kδ) Inhibitor for the Treatment of Immunological Disorders
Qingjie Liu, Qing Shi, David Marcoux, et al.
Journal of Medicinal Chemistry
|
February 18, 2022
Discovery of a Partial Glucokinase Activator Clinical Candidate: Diethyl ((3-(3-((5-(Azetidine-1-carbonyl)pyrazin-2-yl)oxy)-5-isopropoxybenzamido)-1<i>H</i>-pyrazol-1-yl)methyl)phosphonate (BMS-820132)
Yan Shi, Ying Wang, Wei Meng, et al.
Page
of 5